Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Key Points Global survival rate was 74% at a median follow-up after HSCT of 57 months. Preexisting mycobacterial infection and colitis were associated with poor HSCT outcome.

More information

DOI

10.1182/blood-2017-03-771600

Type

Journal article

Publisher

American Society of Hematology

Publication Date

21/09/2017

Volume

130

Pages

1456 - 1467

Total pages

11